Florian Eichhorn1, Hendrik Dienemann2, Thomas Muley2, Arne Warth3, Hans Hoffmann4. 1. Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany. Electronic address: florian.eichhorn@med.uni-heidelberg.de. 2. Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany; German Centre for Lung Research, Heidelberg, Germany. 3. Institute of Pathology, Heidelberg University, Heidelberg, Germany; German Centre for Lung Research, Heidelberg, Germany. 4. Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany.
Abstract
BACKGROUND: Large cell neuroendocrine carcinoma (LCNEC) represents a rare entity in non-small cell lung cancer, with only partially understood biology and poor survival. A diagnosis is difficult to obtain on the basis of small biopsy specimens, but surgical procedures may be indicated in only a small fraction of patients. The aim of this study was to assess the clinical and immunohistochemical features of patients with LCNEC to identify predictors of outcome and long-term survival. METHODS: The clinical and pathologic data of 57 surgical patients with LCNEC between March 2003 and December 2012 were retrospectively reviewed. The tumor specimens were examined for expression of neuronal specific enolase, synaptophysin, CD 56, chromogranin-A, and the somatostatin receptor by immunohistochemistry. Statistical analysis was performed to determine significant predictors for overall survival and recurrence-free survival. RESULTS: Fifty-seven patients (41 men, 16 women) underwent thoracic operations with curative intent. Complete resection was achieved in 91% of cases. The results of staining for CD56, synaptophysin, neuronal specific enolase, chromogranin-A, and somatostatin were positive in 86%, 81%, 68%, 61%, and 21%, respectively. Recurrence occurred in 28 patients (49%). Overall survival and recurrence-free survival were 50% and 45%, respectively, after 3 years. Advanced nodal status (N1, p < 0.025; N2, p < 0.02) and simultaneous expression of CD56 and chromogranin-A (p < 0.04) were significantly associated with poorer outcome. CONCLUSIONS: LCNEC is a rare neuroendocrine pulmonary malignancy that is associated with poor prognosis and high recurrence rates. Surgical treatment can achieve satisfactory results in selected cases. Neuroendocrine marker profiles may predict prognosis and may influence the decision for adjuvant therapy or follow-up intervals.
BACKGROUND: Large cell neuroendocrine carcinoma (LCNEC) represents a rare entity in non-small cell lung cancer, with only partially understood biology and poor survival. A diagnosis is difficult to obtain on the basis of small biopsy specimens, but surgical procedures may be indicated in only a small fraction of patients. The aim of this study was to assess the clinical and immunohistochemical features of patients with LCNEC to identify predictors of outcome and long-term survival. METHODS: The clinical and pathologic data of 57 surgical patients with LCNEC between March 2003 and December 2012 were retrospectively reviewed. The tumor specimens were examined for expression of neuronal specific enolase, synaptophysin, CD 56, chromogranin-A, and the somatostatin receptor by immunohistochemistry. Statistical analysis was performed to determine significant predictors for overall survival and recurrence-free survival. RESULTS: Fifty-seven patients (41 men, 16 women) underwent thoracic operations with curative intent. Complete resection was achieved in 91% of cases. The results of staining for CD56, synaptophysin, neuronal specific enolase, chromogranin-A, and somatostatin were positive in 86%, 81%, 68%, 61%, and 21%, respectively. Recurrence occurred in 28 patients (49%). Overall survival and recurrence-free survival were 50% and 45%, respectively, after 3 years. Advanced nodal status (N1, p < 0.025; N2, p < 0.02) and simultaneous expression of CD56 and chromogranin-A (p < 0.04) were significantly associated with poorer outcome. CONCLUSIONS: LCNEC is a rare neuroendocrine pulmonary malignancy that is associated with poor prognosis and high recurrence rates. Surgical treatment can achieve satisfactory results in selected cases. Neuroendocrine marker profiles may predict prognosis and may influence the decision for adjuvant therapy or follow-up intervals.
Authors: Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla Journal: Sci Transl Med Date: 2015-08-26 Impact factor: 17.956
Authors: Vignesh Raman; Oliver K Jawitz; Chi-Fu J Yang; Soraya L Voigt; Betty C Tong; Thomas A D'Amico; David H Harpole Journal: J Thorac Oncol Date: 2019-09-23 Impact factor: 15.609
Authors: Maria Cattoni; Eric Vallières; Lisa M Brown; Amir A Sarkeshik; Stefano Margaritora; Alessandra Siciliani; Pier Luigi Filosso; Francesco Guerrera; Andrea Imperatori; Nicola Rotolo; Farhood Farjah; Grace Wandell; Kimberly Costas; Catherine Mann; Michal Hubka; Stephen Kaplan; Alexander S Farivar; Ralph W Aye; Brian E Louie Journal: World J Surg Date: 2019-07 Impact factor: 3.352
Authors: Pier Luigi Filosso; Piero Ferolla; Francesco Guerrera; Enrico Ruffini; William D Travis; Giulio Rossi; Paolo Olivo Lausi; Alberto Oliaro Journal: J Thorac Dis Date: 2015-04 Impact factor: 2.895